Mabpharm Limited

SEHK:2181 Stock Report

Market Cap: HK$2.2b

Mabpharm Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Hao Wang

Chief executive officer

CN¥5.6m

Total compensation

CEO salary percentage19.34%
CEO tenure7.3yrs
CEO ownershipn/a
Management average tenure7yrs
Board average tenure6.3yrs

Recent management updates

We Think Some Shareholders May Hesitate To Increase Mabpharm Limited's (HKG:2181) CEO Compensation

Jun 11
We Think Some Shareholders May Hesitate To Increase Mabpharm Limited's (HKG:2181) CEO Compensation

Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now

Jun 14
Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now

Recent updates

Mabpharm Limited's (HKG:2181) Low P/S No Reason For Excitement

Oct 31
Mabpharm Limited's (HKG:2181) Low P/S No Reason For Excitement

Here's Why Mabpharm (HKG:2181) Can Afford Some Debt

Sep 29
Here's Why Mabpharm (HKG:2181) Can Afford Some Debt

Why Investors Shouldn't Be Surprised By Mabpharm Limited's (HKG:2181) Low P/S

Jul 28
Why Investors Shouldn't Be Surprised By Mabpharm Limited's (HKG:2181) Low P/S

We Think Some Shareholders May Hesitate To Increase Mabpharm Limited's (HKG:2181) CEO Compensation

Jun 11
We Think Some Shareholders May Hesitate To Increase Mabpharm Limited's (HKG:2181) CEO Compensation

Is Mabpharm (HKG:2181) Using Too Much Debt?

Mar 27
Is Mabpharm (HKG:2181) Using Too Much Debt?

There's Reason For Concern Over Mabpharm Limited's (HKG:2181) Massive 45% Price Jump

Feb 19
There's Reason For Concern Over Mabpharm Limited's (HKG:2181) Massive 45% Price Jump

Investors Don't See Light At End Of Mabpharm Limited's (HKG:2181) Tunnel

Dec 22
Investors Don't See Light At End Of Mabpharm Limited's (HKG:2181) Tunnel

Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now

Jun 14
Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now

More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%

Jan 24
More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%

Mabpharm (HKG:2181) Is Making Moderate Use Of Debt

Oct 20
Mabpharm (HKG:2181) Is Making Moderate Use Of Debt

Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Jan 18
Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Oct 07
Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation

Apr 28
Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation

Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?

Mar 03
Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?

We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate

Jan 27
We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate

Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?

Dec 09
Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?

CEO Compensation Analysis

How has Hao Wang's remuneration changed compared to Mabpharm's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

-CN¥27m

Mar 31 2025n/an/a

-CN¥78m

Dec 31 2024CN¥6mCN¥1m

-CN¥128m

Sep 30 2024n/an/a

-CN¥167m

Jun 30 2024n/an/a

-CN¥207m

Mar 31 2024n/an/a

-CN¥208m

Dec 31 2023CN¥6mCN¥1m

-CN¥209m

Sep 30 2023n/an/a

-CN¥202m

Jun 30 2023n/an/a

-CN¥194m

Mar 31 2023n/an/a

-CN¥202m

Dec 31 2022CN¥3mCN¥1m

-CN¥211m

Sep 30 2022n/an/a

-CN¥237m

Jun 30 2022n/an/a

-CN¥263m

Mar 31 2022n/an/a

-CN¥278m

Dec 31 2021CN¥5mCN¥1m

-CN¥292m

Compensation vs Market: Hao's total compensation ($USD788.06K) is above average for companies of similar size in the Hong Kong market ($USD328.34K).

Compensation vs Earnings: Hao's compensation has been consistent with company performance over the past year.

CEO

Hao Wang (56 yo)

7.3yrs
Tenure
CN¥5,573,000
Compensation

Dr. Hao Wang serves as Chief Executive Officer and Executive Director at Mabpharm Limited since October 28, 2020 and July 20, 2018 respectively and also serves as Chief Scientist since August 2018. Dr. Wan...

Leadership Team

NamePositionTenureCompensationOwnership
Hao Wang
Chief Scientist7.3yrsCN¥5.57mno data
Jing Tao
VP & Executive Directorno dataCN¥1.58mno data
Sheng Hou
VP & Executive Director2.1yrsCN¥780.00kno data
Weizhu Qian
VP & Executive Director1.4yrsCN¥5.64mno data
Yunfeng Li
VP, Joint Company Secretary & Executive Director7.3yrsCN¥1.58mno data
Ho Yin Tsang
Joint Company Secretary6.6yrsno datano data
Jing Li
Vice President7.3yrsCN¥1.40mno data
7.0yrs
Average Tenure
49yo
Average Age

Experienced Management: 2181's management team is seasoned and experienced (7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Hao Wang
Chief Scientist7.4yrsCN¥5.57mno data
Jing Tao
VP & Executive Director5.2yrsCN¥1.58mno data
Sheng Hou
VP & Executive Director2.1yrsCN¥780.00kno data
Weizhu Qian
VP & Executive Director2.1yrsCN¥5.64mno data
Yunfeng Li
VP, Joint Company Secretary & Executive Director7.4yrsCN¥1.58mno data
Shuge Jiao
Non-Executive Chairman7.4yrsno datano data
Liangzhong Guo
Independent Non-Executive Director7.3yrsCN¥98.00kno data
Yanyun Zhang
Lead Independent Non-Executive Director7.3yrsCN¥98.00kno data
Jialin Cen
Non-Executive Director1.4yrsno datano data
Qian Tao
Independent Non-Executive Director1.4yrsCN¥57.00kno data
6.3yrs
Average Tenure
54yo
Average Age

Experienced Board: 2181's board of directors are considered experienced (6.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/01 04:45
End of Day Share Price 2025/12/01 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Mabpharm Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yue-Kwong LuiJefferies LLC